PISCATAWAY, N.J., Aug. 8, 2025 /PRNewswire/ -- GenScript Biotech Corporation (HK.1548), a global leader in life sciences innovation, today unveiled its new global brand platform: Scripting ...

The share-price surge came as promising cancer trial data overshadowed continuing scrutiny of China's biotechnology sector by US lawmakers GenScript Biotech Holdings surged in Hong Kong after its ...

Recent price moves and business snapshot Genscript Biotech (SEHK:1548) has seen the stock slip about 0.5% on the day and roughly 5.6% over the past week, while posting a gain of around 13% over the ...

In the rapidly evolving world of cancer treatments, CAR-T cell therapy stands out for its effectiveness tackling hematologic tumors. Booming demand for such therapies powered Legend Biotech Corp. LEGN ...

(Reuters) -The U.S. House of Representatives committee on China on Tuesday sent a letter to the directors of the FBI and national intelligence, renewing its concerns about GenScript Biotechnology's ...

The two biotech leaders have embarked on a research project to streamline manufacturing The two biotech leaders have embarked on a research project to streamline manufacturing GenScript – the ...

Join us as we delve into the forefront of SARS-CoV-2 diagnostics and GenScript's transformative impact in the fight against COVID-19. We'll discuss the emergence of COVID-19 and GenScript's rapid ...

No-moat GenScript’s 01548 full-year results were in line with our expectations. Companywide revenue for the year was within 2% of our expectations. However, revenue growth from the non-cell therapy ...

GenScript ProBio is the subsidiary of GenScript Biotech Corp. (HK.1548), building upon GenScript’s solid gene synthesis technology and deep expertise in the antibody, cell, and gene therapy fields, ...

GenScript is delighted to announce its 2nd Annual Virtual Summit on Gene and Cell Engineering. This gathering will feature leaders in the life sciences from academia, pharma, and biotech, leveraging ...

Legend Biotech, a Group subsidiary, continued to drive progress in its cell therapy business. It achieved a series of key milestones, including a successful Nasdaq IPO and the submission of Biologics ...